Rodney Varner, President and CEO of Genprex, joins CEO Roadshow’s Mike Elliott to talk about the company’s gene therapies for cancer and diabetes.
The triple combination of chemotherapy, immunotherapy (immune checkpoint blockade) and REQORSA demonstrated strong antitumor efficacy and induced robust antitumor immunity in KRAS-LKB1 (KL)-mutant NSCLC in clinically relevant humanized mice models.
Dr. George Gittes, the inventor of the diabetes gene therapy, GPX-002, discusses paradigm shifts in diabetes and pediatric medicine with Progress, Potential, and Possibilities’ Ira S. Pastor.
Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner tells Proactive it has met the necessary specifications and passed the final release tests for its first manufacturing run of REQORSA immunogene therapy in advance of non-small cell lung cancer (NSCLC) clinical trials.
Genprex, Inc. (NASDAQ:GNPX) CEO Rodney Varner tells Proactive the Texas-based group has launched new branding for the upcoming oncology clinical trials combining its lead drug candidate REQORSA with AstraZeneca’s Tagrisso and separately with Merck’s Keytruda for the treatment of non-small cell lung cancer (NSCLC).
Genprex participates in Noble Capital Markets’ C-Suite Interview Series, presented by Channelchek, led by Noble Capital Markets Biotechnology Analyst Ahu Demir, Ph.D.
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, participates in a live interview with the “Big Biz Show” for a second time, providing details on its lead drug candidate for NSCLC, its diabetes gene therapy and what lies ahead in the next 18 months in the midst of COVID-19.
Genprex, Inc. (NASDAQ:GNPX) CEO Rodney Varner talks to Proactive’s Christine Corrado about the Texas-based biotechnology company’s most recent updates. Namely, Varner says the firm has approved the generic name quaratusugene ozeplasmid, for its non-small cell lung cancer drug formerly known as Oncoprex. What’s more, its ramping up the production of its drug for upcoming clinical trials, and the company has joined the Russell 3000 index.
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, participates in a live interview with the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show to discuss the company’s gene therapy technologies.
Genprex’s Chairman and Chief Executive Officer, Rodney Varner, participates in a live interview with the “Big Biz Show,” an emmy-award winning nationally syndicated TV and radio show to discuss the company’s gene therapy technologies.